Lucentis wins 1st US FDA OK for diabetic eye disease
This article was originally published in Scrip
Executive Summary
Roche US unit Genentech was granted the OK from the US FDA on 10 August to market Lucentis (ranibizumab) as the first drug in the US to treat diabetic macular edema (DME), an eye condition that affects about 560,000 Americans with diabetes, causing blurred vision, severe vision loss and sometimes blindness.